Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1Breast 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Ovarian Neoplasms 4Pancreatic Neoplasms 3Colorectal Neoplasms, Hereditary Nonpolyposis 3Triple Negative Breast Neoplasms 2Neoplastic Syndromes, Hereditary 2Hereditary Breast and Ovarian Cancer Syndrome 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urogenital Neoplasms 1Sarcoma 1Rectal Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Melanoma 1Lymphoproliferative Disorders 1Kidney Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Fanconi Anemia, Complementation Group D1 1Digestive System Neoplasms 1Cytopenia 1Congenital Bone Marrow Failure Syndromes 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Risk Syndrome 1Breast Neoplasms, Male 1

Interventions

olaparib 9Carboplatin 3talazoparib 1pembrolizumab 1liposomal doxorubicin 1iniparib 1Trabectedin 1Paclitaxel 1Genetic Counseling 1Counseling 1ABT-767 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fanconi Anemia, Complementation Group D1 × Genetic Counseling × Clear all
NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Dana-Farber Cancer Institute

Phase NA Completed
150 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡